Copper signaling axis as a target for prostate cancer therapeutics

Rachid Safi, Erik R. Nelson, Satish K. Chitneni, Katherine J. Franz, Daniel J. George, Michael R. Zalutsky, Donald P. McDonnell

Research output: Contribution to journalArticle

Abstract

Previously published reports indicate that serum copper levels are elevated in patients with prostate cancer and that increased copper uptake can be used as a means to image prostate tumors. It is unclear, however, to what extent copper is required for prostate cancer cell function as we observed onlymodest effects of chelation strategies on the growth of these cells in vitro. With the goal of exploiting prostate cancer cell proclivity for copper uptake, we developed a "conditional lethal" screen to identify compounds whose cytotoxic actions were manifested in a copper-dependent manner. Emerging from this screen was a series of dithiocarbamates, which, when complexed with copper, induced reactive oxygen species-dependent apoptosis of malignant, but not normal, prostate cells. One of the dithiocarbamates identified, disulfiram (DSF), is an FDA-approved drug that has previously yielded disappointing results in clinical trials in patients with recurrent prostate cancer. Similarly, in our studies, DSF alone had a minimal effect on the growth of prostate cancer tumors when propagated as xenografts. However, when DSF was coadministered with copper, a very dramatic inhibition of tumorgrowth inmodels of hormone-sensitive and of castrate-resistant disease was observed. Furthermore, we determined that prostate cancer cells express high levels of CTR1, the primary copper transporter, and additional chaperones that are required to maintain intracellular copper homeostasis. The expression levels of most of these proteins are increased further upon treatment of androgen receptor (AR)-positive prostate cancer cell lines with androgens. Not surprisingly, robust CTR1- dependent uptake of copper into prostate cancer cells was observed, an activity that was accentuated by activation of AR. Given these data linking AR to intracellular copper uptake, we believe that dithiocarbamate/copper complexes are likely to be effective for the treatment of patients with prostate cancer whose disease is resistant to classical androgen ablation therapies.

Original languageEnglish (US)
Pages (from-to)5819-5831
Number of pages13
JournalCancer Research
Volume74
Issue number20
DOIs
StatePublished - Oct 15 2014

Fingerprint

Copper
Prostatic Neoplasms
Disulfiram
Androgen Receptors
Therapeutics
Androgens
Prostate
Growth
Heterografts
Reactive Oxygen Species
Neoplasms
Homeostasis
Clinical Trials
Hormones
Apoptosis
Cell Line

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Cite this

Safi, R., Nelson, E. R., Chitneni, S. K., Franz, K. J., George, D. J., Zalutsky, M. R., & McDonnell, D. P. (2014). Copper signaling axis as a target for prostate cancer therapeutics. Cancer Research, 74(20), 5819-5831. https://doi.org/10.1158/0008-5472.CAN-13-3527

Copper signaling axis as a target for prostate cancer therapeutics. / Safi, Rachid; Nelson, Erik R.; Chitneni, Satish K.; Franz, Katherine J.; George, Daniel J.; Zalutsky, Michael R.; McDonnell, Donald P.

In: Cancer Research, Vol. 74, No. 20, 15.10.2014, p. 5819-5831.

Research output: Contribution to journalArticle

Safi, R, Nelson, ER, Chitneni, SK, Franz, KJ, George, DJ, Zalutsky, MR & McDonnell, DP 2014, 'Copper signaling axis as a target for prostate cancer therapeutics', Cancer Research, vol. 74, no. 20, pp. 5819-5831. https://doi.org/10.1158/0008-5472.CAN-13-3527
Safi R, Nelson ER, Chitneni SK, Franz KJ, George DJ, Zalutsky MR et al. Copper signaling axis as a target for prostate cancer therapeutics. Cancer Research. 2014 Oct 15;74(20):5819-5831. https://doi.org/10.1158/0008-5472.CAN-13-3527
Safi, Rachid ; Nelson, Erik R. ; Chitneni, Satish K. ; Franz, Katherine J. ; George, Daniel J. ; Zalutsky, Michael R. ; McDonnell, Donald P. / Copper signaling axis as a target for prostate cancer therapeutics. In: Cancer Research. 2014 ; Vol. 74, No. 20. pp. 5819-5831.
@article{e8c7fba6dba14142a0b6b27f08316158,
title = "Copper signaling axis as a target for prostate cancer therapeutics",
abstract = "Previously published reports indicate that serum copper levels are elevated in patients with prostate cancer and that increased copper uptake can be used as a means to image prostate tumors. It is unclear, however, to what extent copper is required for prostate cancer cell function as we observed onlymodest effects of chelation strategies on the growth of these cells in vitro. With the goal of exploiting prostate cancer cell proclivity for copper uptake, we developed a {"}conditional lethal{"} screen to identify compounds whose cytotoxic actions were manifested in a copper-dependent manner. Emerging from this screen was a series of dithiocarbamates, which, when complexed with copper, induced reactive oxygen species-dependent apoptosis of malignant, but not normal, prostate cells. One of the dithiocarbamates identified, disulfiram (DSF), is an FDA-approved drug that has previously yielded disappointing results in clinical trials in patients with recurrent prostate cancer. Similarly, in our studies, DSF alone had a minimal effect on the growth of prostate cancer tumors when propagated as xenografts. However, when DSF was coadministered with copper, a very dramatic inhibition of tumorgrowth inmodels of hormone-sensitive and of castrate-resistant disease was observed. Furthermore, we determined that prostate cancer cells express high levels of CTR1, the primary copper transporter, and additional chaperones that are required to maintain intracellular copper homeostasis. The expression levels of most of these proteins are increased further upon treatment of androgen receptor (AR)-positive prostate cancer cell lines with androgens. Not surprisingly, robust CTR1- dependent uptake of copper into prostate cancer cells was observed, an activity that was accentuated by activation of AR. Given these data linking AR to intracellular copper uptake, we believe that dithiocarbamate/copper complexes are likely to be effective for the treatment of patients with prostate cancer whose disease is resistant to classical androgen ablation therapies.",
author = "Rachid Safi and Nelson, {Erik R.} and Chitneni, {Satish K.} and Franz, {Katherine J.} and George, {Daniel J.} and Zalutsky, {Michael R.} and McDonnell, {Donald P.}",
year = "2014",
month = "10",
day = "15",
doi = "10.1158/0008-5472.CAN-13-3527",
language = "English (US)",
volume = "74",
pages = "5819--5831",
journal = "Cancer Research",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "20",

}

TY - JOUR

T1 - Copper signaling axis as a target for prostate cancer therapeutics

AU - Safi, Rachid

AU - Nelson, Erik R.

AU - Chitneni, Satish K.

AU - Franz, Katherine J.

AU - George, Daniel J.

AU - Zalutsky, Michael R.

AU - McDonnell, Donald P.

PY - 2014/10/15

Y1 - 2014/10/15

N2 - Previously published reports indicate that serum copper levels are elevated in patients with prostate cancer and that increased copper uptake can be used as a means to image prostate tumors. It is unclear, however, to what extent copper is required for prostate cancer cell function as we observed onlymodest effects of chelation strategies on the growth of these cells in vitro. With the goal of exploiting prostate cancer cell proclivity for copper uptake, we developed a "conditional lethal" screen to identify compounds whose cytotoxic actions were manifested in a copper-dependent manner. Emerging from this screen was a series of dithiocarbamates, which, when complexed with copper, induced reactive oxygen species-dependent apoptosis of malignant, but not normal, prostate cells. One of the dithiocarbamates identified, disulfiram (DSF), is an FDA-approved drug that has previously yielded disappointing results in clinical trials in patients with recurrent prostate cancer. Similarly, in our studies, DSF alone had a minimal effect on the growth of prostate cancer tumors when propagated as xenografts. However, when DSF was coadministered with copper, a very dramatic inhibition of tumorgrowth inmodels of hormone-sensitive and of castrate-resistant disease was observed. Furthermore, we determined that prostate cancer cells express high levels of CTR1, the primary copper transporter, and additional chaperones that are required to maintain intracellular copper homeostasis. The expression levels of most of these proteins are increased further upon treatment of androgen receptor (AR)-positive prostate cancer cell lines with androgens. Not surprisingly, robust CTR1- dependent uptake of copper into prostate cancer cells was observed, an activity that was accentuated by activation of AR. Given these data linking AR to intracellular copper uptake, we believe that dithiocarbamate/copper complexes are likely to be effective for the treatment of patients with prostate cancer whose disease is resistant to classical androgen ablation therapies.

AB - Previously published reports indicate that serum copper levels are elevated in patients with prostate cancer and that increased copper uptake can be used as a means to image prostate tumors. It is unclear, however, to what extent copper is required for prostate cancer cell function as we observed onlymodest effects of chelation strategies on the growth of these cells in vitro. With the goal of exploiting prostate cancer cell proclivity for copper uptake, we developed a "conditional lethal" screen to identify compounds whose cytotoxic actions were manifested in a copper-dependent manner. Emerging from this screen was a series of dithiocarbamates, which, when complexed with copper, induced reactive oxygen species-dependent apoptosis of malignant, but not normal, prostate cells. One of the dithiocarbamates identified, disulfiram (DSF), is an FDA-approved drug that has previously yielded disappointing results in clinical trials in patients with recurrent prostate cancer. Similarly, in our studies, DSF alone had a minimal effect on the growth of prostate cancer tumors when propagated as xenografts. However, when DSF was coadministered with copper, a very dramatic inhibition of tumorgrowth inmodels of hormone-sensitive and of castrate-resistant disease was observed. Furthermore, we determined that prostate cancer cells express high levels of CTR1, the primary copper transporter, and additional chaperones that are required to maintain intracellular copper homeostasis. The expression levels of most of these proteins are increased further upon treatment of androgen receptor (AR)-positive prostate cancer cell lines with androgens. Not surprisingly, robust CTR1- dependent uptake of copper into prostate cancer cells was observed, an activity that was accentuated by activation of AR. Given these data linking AR to intracellular copper uptake, we believe that dithiocarbamate/copper complexes are likely to be effective for the treatment of patients with prostate cancer whose disease is resistant to classical androgen ablation therapies.

UR - http://www.scopus.com/inward/record.url?scp=84908122752&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84908122752&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-13-3527

DO - 10.1158/0008-5472.CAN-13-3527

M3 - Article

C2 - 25320179

AN - SCOPUS:84908122752

VL - 74

SP - 5819

EP - 5831

JO - Cancer Research

JF - Cancer Research

SN - 0008-5472

IS - 20

ER -